Claims
- 1. A compound of the formula: whereinX is —O—, —S—, —NH—, or —N(R2) —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino; R1 is —CR24R27—(CR23R27)n— —CR24R27—(CR23R24)n—CR24R27—, where n is 0, 1, 2 or 3; or —CHR24CH═CH—CHR24 —CHR24—CH═CH—CHR24—, —CHR24—C≡C—CHR24—, —CHR24—CH═CH—CR23R24—CHR24—, —CHR24—CR23R24—CH═CH—CHR24—, —CHR24—CH≡C—CR23R24—CHR24 —CHR24—C≡C—CR23R24—CHR24—, or —CHR24—CR23R24—C≡C—CHR24 —CHR24—CR23R24—C≡C—CHR24—, the —CH═CH— bond being cis or trans; R23 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy, (C1-C18)alkoxy, aryloxy, aryl(C1-C18)alkyloxy, (C1-C18)alkanoyloxy, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl(C1-C6)alkyloxy, aryl(C1-C18)alkoxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C18)alkyl or whereZ1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2, or halogen, and p is as previously defined; R24 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl(C1-C6)alkyloxy, aryl(C1-C18)alkyoxy alkyloxy(C1-C6)alkyl or (C1-C18)alkanoyloxy(C1-C6)alkyl or whereZ1 and p are as previously defined; R27 is hydrogen or R24 and R27 taken together with the carbon to which they are attached form C═O or C═S; Q2 is S, NH, or —CH2 —S—, —NH—, or —CH2—; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, diakylaminocarbonyl dialkylaminocarbonyl, formyl, —C(═O)—alkyl, —C(═O)—O-alkyl, —C(═O)-aryl, —C(═O)-heteroaryl, —CH(OR7)-alkyl, —C(═W)-alkyl, —C(═W)-aryl, or —C(═W)-heteroaryl; alkyl is (C1-C18)alkyl; aryl is phenyl or whereR5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoakylamino monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is Q3 is —O—, —S—, —NH—, —CH═N—; W is CH2 or CHR8 or N—R9; R7 is hydrogen, lower alkyl, or alkanoyl; R8 is lower alkyl; R9 is hydroxy, alkoxy, or —NHR10; and R10 is hydrogen, lower alkyl, C1-C3 acyl (C1-C3)acyl, aryl, —C(═O)-aryl or —C(═O)—heteroaryl, where aryl and heteroaryl are as defined above; and m is 1, 2 or 3; with the exclusion of a compound wherein X is —S—, Q2 is —CH2—, Y is hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy or trifluoromethyl, and p is 1 or 2; with the exclusion of a compound wherein X is —N(R2)—, Q2 is —CH2—, R is chlorine, fluorine, bromine, iodine, lower alkyl, lower alkoxy, lower alkyl thio, lower monoalkylamino, lower dialkylamino, amino, cyano, hydroxy, or trifluoromethyl, R2 is aryl, Y is hydrogen, halogen, lower alkyl, lower alkoxy or hydroxy, and p is 1 or 2; with the exclusion of a compound wherein X is —NH— or —N(R2)—, R2 is lower alkyl, aryl lower alkyl, or phenylsulfonyl, Y is hydrogen, halogen, lower alkyl, lower alkoxy, or hydroxy, p is 1 or 2; and Q2 is —CH2—; with the proviso that R23 is not hydrogen, (C1-C18)linear alkyl, phenyl, or when R27 is hydrogen and R24 is hydrogen, (C1-C18)linear alkyl, phenyl, or with the proviso that R24 is not hydrogen, (C1-C18)linear alkyl, phenyl, or when R27 is hydrogen and n is 0; or when R27 is hydrogen and R23 is hydrogen, (C1-C18)linear alkyl, phenyl, or or when R1 is —CHR24—CH═CH—CHR24— or —CHR24—C≡C—CHR24—; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively by acylated with a (C4-C18)alkoxycarbonyl group; andall geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 2. The compound of claim 1, wherein X is —N(R2)—.
- 3. The compound of claim 1, wherein R2 is (C1-C18)alkanoyl or (C1-C18)alkoxycarbonyl.
- 4. An antipsychotic composition, which comprises the compound of claim 1 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.
- 5. A method of treating psychoses, which comprises administrating to a mammal a psychoses-treating effective amount of the compound of claim 1.
- 6. An analgesic composition, which comprises the compound of claim 1 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.
- 7. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 1.
- 8. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 1, wherein the compound contains a hydroxy group, an amino group, or a nitrogen at the 1-position of an indazole ring, which has been acylated.
- 9. The depot pharmaceutical composition of claim 8, wherein the hydroxy group or amino group is acylated with an (C4-C18)alkanoyl group or an (C4-C18)alkoxycarbonyl group.
- 10. The composition of claim 8, which contains a pharmaceutically acceptable oil.
- 11. The composition of claim 10, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and ester of fatty acids and polyfunctional alcohols.
- 12. The composition of claim 9, which contains a pharmaceutically acceptable oil.
- 13. The composition of claim 12, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 14. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 8 sufficient to produce a long acting antipsychotic effect.
- 15. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 9 sufficient to produce a long acting antipsychotic effect.
- 16. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 13 sufficient to produce a long acting antipsychotic effect.
- 17. A compound of the formula wherein X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro or amino, when p is 1; Y is lower alkoxy, hydroxy, or halogen, when p is 2 and X is —O—; in which (R1) is R20, R21, or R22, wherein: R20 is —(CH2)n—, where n is 2, 3, 4 or 5; R21 is —CH2—CH═CH—CH2—, —CH2—C≡C—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2—CH2—CH═CH—CH2—, —CH2—C≡C—CH2—CH2—, or —CH2—CH2—C≡C—CH2—, the —CH═CH— bond being cis or trans; R22 is R20 or R21 in which one or more carbon atoms of R20 or R21 are substituted by at least one C1-C6 linear alkyl group, phenyl group, or Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2, or halogen, and p is as previously defined; and Q2 is —S—, —NH—, or —CH2—; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, —C(═O)-alkyl —C(═O)—O-alkyl, —C(═O)-aryl, —C(═O)-heteroaryl, —CH(OR7)-alkyl, —C(═W)-alkyl, —C(═W)-aryl, or —C(═W)-heteroaryl; alkyl is (C1-C6)alkyl; aryl is phenyl or where R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is Q3 is —O—, —S—, —NH—, or —CH═N—; W is CH2, CHR8 or N—R9; R7 is hydrogen, lower alkyl, or acyl; R8 is lower alkyl; R9 is hydroxy, alkoxy, or —NHR10; and R10 is hydrogen, lower alkyl, (C1-C3)acyl, aryl, —C(═O)-aryl, or —C(═O)-heteroaryl, where aryl and heteroaryl are as defined above; and m is 1, 2 or 3; with the proviso that Q2 is not —CH2— when X is —S— and Y is hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy or trifluoromethyl; with the proviso that Q2 is not —CH2— when X is —N(R2)—, R2 is aryl, and R is hydrogen, chlorine, fluorine, bromine, iodine, lower alkyl, lower alkoxy, lower alkyl thio, lower monoalkylamino, lower dialkylamino, amino, nitro, cyano, hydroxy, or trifluoromethyl; with the proviso that Q2 is not —CH2— when X is —NH— or —N(R2)—, where R2 is lower alkyl, aryl lower alkyl, or phenylsulfonyl; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 18. A pharmaceutical composition which comprises a compound of claim 17 and a pharmaceutically acceptable carrier therefor.
- 19. The compound of claim 17, wherein X is —N(R2)—.
- 20. The compound of claim 17, wherein R2 is (C2-C11)alkanoyl.
- 21. An antipsychotic composition, which comprises the compound of claim 17 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.
- 22. A method of treating psychoses, which comprises administrating to a mammal a psychoses-treating effective amount of the compound of claim 17.
- 23. An analgesic composition, which comprises the compound of claim 17 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.
- 24. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 17.
- 25. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula: wherein X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy, or halogen, when p is 2 and X is —O—; in which (R1) is R20, R21, or R22, wherein: R20 is —(CH2)n—, where n is 2, 3, 4, or 5; R21 is —CH2—CH═CH—CH2—, —CH2—C≡C—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2—CH2—CH═CH—CH2—, —CH2—C≡C—CH2—CH2—, or —CH2—CH2—C≡C—CH2—, the —CH═CH— bond being cis or trans; R22 is R20 or R21 in which one or more carbon atoms of R20 or R21 are substituted by at least one C1-C6 linear alkyl group, phenyl group, or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2, or halogen, and p is as previously defined; and Q2 is —S—, —NH—, or —CH2—; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, —C(═O)-alkyl —C(═O)—O-alkyl, —C(═O)-aryl, —C(═O)-heteroaryl, —CH(OR7)-alkyl, —C(═W)-alkyl, —C(═W)-aryl, or —C(═W)-heteroaryl; alkyl is (C1-C6)alkyl; aryl is phenyl or where R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is Q3 is —O—, —S—, —NH—, or —CH═N—; W is CH2, CHR8, or N—R9; R7 is hydrogen, lower alkyl, or acyl; R8 is lower alkyl; R9 is hydroxy, alkoxy, or —NHR10; and R10 is hydrogen, lower alkyl, (C1-C3)acyl, aryl, —C(═O)-aryl or —C(═O)-heteroaryl, where aryl and heteroaryl are as defined above; and m is 1, 2 or 3; with the proviso that Q2 is not —CH2— when X is —S— and Y is hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy or trifluoromethyl; with the proviso that Q2 is not —CH2— when X is —N(R2)—, R2 is aryl, and R is hydrogen, chlorine, fluorine, bromine, iodine, lower alkyl, lower alkoxy, lower alkyl thio, lower monoalkylamino, lower dialkylamino, amino, nitro, cyano, hydroxy, or trifluoromethyl; with the proviso that Q2 is not —CH2— when X is —NH— or —N(R2)—, where R2 is lower alkyl, aryl lower alkyl, or phenylsulfonyl; wherein any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; and all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 26. The depot pharmaceutical composition of claim 25, wherein the hydroxy group or amino group is acylated with an (C4-C18)alkanoyl group or an (C4-C18)alkoxycarbonyl group.
- 27. The depot composition of claim 25, which contains a pharmaceutically acceptable oil.
- 28. The depot composition of claim 27, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and ester of fatty acids and polyfunctional alcohols.
- 29. The depot composition of claim 26, which contains a pharmaceutically acceptable oil.
- 30. The depot composition of claim 29, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 31. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 25 sufficient to produce a long acting antipsychotic effect.
- 32. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 26 sufficient to produce a long acting antipsychotic effect.
- 33. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 30 sufficient to produce a long acting antipsychotic effect.
- 34. A compound of the formula: wherein X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 2; Y is lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethoxy, nitro or amino when X is —S—, —NH—, or —N(R2)—; Y is lower alkyl, trifluoromethoxy, nitro or amino when X is —O—; R1 is —CR24R27—(CR23R24)n—CR24R27—, where n is 0, 1, 2 or 3; or —CHR24—CH═CH—CHR24—, —CHR24—C≡C—CHR24—, —CHR24—CH═CH—CR23R24—CHR24—, —CHR24—CR23R24—CH═CH—CHR24—, —CHR24—C≡C—CR23R24—CHR24—, or —CHR24—CR23R24—C≡C—CHR24—, the —CH═CH— bond being cis or trans; R23 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy, (C1-C18)alkoxy, aryloxy, aryl(C1-C18)alkyloxy, (C1-C18)alkanoyloxy, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, aryl(C1-C18)alkoxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C18)alkyl or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2, or halogen, and p is as previously defined; R24 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl(C1-C6)alkyloxy, aryl(C1-C18)alkyloxy(C1-C6)alkyl or (C1-C18)alkanoyloxy(C1-C6)alkyl or where Z1 and p are as previously defined; R27 is hydrogen or R24 and R27 taken together with the carbon to which they are attached form C═O or C═S; O2 is —S—, —NH—, or —CH2—; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, —C(═O)-alkyl —C(═O)—O-alkyl, —C(═O)-aryl, —C(═O)-heteroaryl, —CH(OR7)-alkyl, —C(═W)-alkyl, —C(═W)-aryl, or —C(═W)-heteroaryl; alkyl is (C1-C18)alkyl; aryl is phenyl or where R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroary is Q3 is —O—, —S—, —NH—, —CH═N—; W is CH2 or CHR8 or N—R9; R7 is hydrogen, lower alkyl, or alkanoyl; R8 is lower alkyl; R9 is hydroxy, alkoxy, or —NHR10; and R10 is hydrogen, lower alkyl, (C1-C3)acyl, aryl, —C(═O)-aryl or —C(═O)-heteroaryl, where aryl and heteroaryl are as defined above; and m is 1, 2 or 3; with the proviso that Q2 is not —CH2— when X is —S— and Y is hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy or trifluoromethyl; with the proviso that Q2 is not —CH2— when X is —NH— or —N(R2)—, where R2 is lower alkyl, aryl lower alkyl, or phenylsulfonyl; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternately be acylated with a (C4-C18)alkoxycarbonyl group; and all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 35. The compound of claim 34, wherein X is —N(R2)—.
- 36. The compound of claim 34, wherein R2 is (C1-C18)alkanoyl or (C1-C18)alkoxycarbonyl.
- 37. An antipsychotic composition, which comprises the compound of claim 34 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.
- 38. A method of treating psychoses, which comprises administrating to a mammal a psychoses-treating effective amount of the compound of claim 34.
- 39. An analgesic composition, which comprises the compound of claim 34 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.
- 40. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 34.
- 41. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 34, wherein any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group.
- 42. The depot pharmaceutical composition of claim 41, wherein the hydroxy group or amino group is acylated with an (C4-C18)alkanoyl group or an (C4-C18)alkyloxycarbonyl group.
- 43. The composition of claim 41, which contains a pharmaceutically acceptable oil.
- 44. The composition of claim 43, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and ester of fatty acids and polyfunctional alcohols.
- 45. The composition of claim 42, which contains a pharmaceutically acceptable oil.
- 46. The composition of claim 45, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 47. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 41 sufficient to produce a long acting antipsychotic effect.
- 48. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 42 sufficient to produce a long acting antipsychotic effect.
- 49. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 46 sufficient to produce a long acting antipsychotic effect.
CROSS-REFERENCE TO RELATED APPLICATION
This is a reissue of Ser. No. 08/466,845 filed Jun. 6, 1995 now U.S. Pat. No. 5,583,145 and a division of application Ser. No. 08/329,000 filed Oct. 25, 1994 of Joseph T. Strupczewski, Grover C. Helsley, Edward J. Glamkowski, Yulin Chiang, Kennet J. Bordeau, Peter A. Nemoto and John. J. Tegeler for HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS U.S. Pat. No. 5,776,963, which is a CIP application of Ser. No. 08/144,265, filed Oct. 28, 1993, abandoned, which is a CIP application of Ser. No. 07/969,383, filed Oct. 30, 1992, U.S. Pat. No. 5,364,866 which is a CIP application of Ser. No. 07/788,269, filed Nov. 5, 1991, now abandoned, which is a CIP application of Ser. No. 07/944,705, filed Sep. 5, 1991, now abandoned, which is a continuation application of Ser. No. 07/619,825, filed Nov. 29, 1990, now abandoned, which is a continuation application of Ser. No. 07/465,790, filed Dec. 29, 1989, now abandoned, which is a CIP application of Ser. No. 07/354,411, filed May, 19, 1989, now abandoned.
US Referenced Citations (15)
Foreign Referenced Citations (23)
Number |
Date |
Country |
353 0089 |
Mar 1986 |
DE |
2 503 816 |
Jul 1975 |
DK |
0 013 612 |
Jul 1980 |
EP |
0 135 781 |
Apr 1985 |
EP |
0 196 096 |
Oct 1986 |
EP |
0 261 688 |
Mar 1988 |
EP |
0 302 423 |
Feb 1989 |
EP |
0 314 098 |
May 1989 |
EP |
0 329 168 |
Aug 1989 |
EP |
0 353 821 |
Feb 1990 |
EP |
0 357 134 |
Mar 1990 |
EP |
0 398 425 |
Nov 1990 |
EP |
0 402 644 |
Dec 1990 |
EP |
0 464 846 |
Jan 1992 |
EP |
0 542 136 A1 |
May 1993 |
EP |
2 163 432 |
Feb 1986 |
GB |
233 710 |
May 1990 |
NZ |
233 503 |
Jun 1991 |
NZ |
233 525 |
Sep 1991 |
NZ |
WO9309102 |
May 1993 |
WO |
WO9316073 |
Aug 1993 |
WO |
WO16703 |
Sep 1993 |
WO |
WO9418196 |
Aug 1994 |
WO |
Non-Patent Literature Citations (1)
Entry |
Fuller, R.W., Drugs Acting on Serotonergic Neuronal Systems, Biology of Serotonergic Transmission, John Wiley & Sons Ltd., 1982, pp. 221-247. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
08/466895 |
Jun 1995 |
US |
Child |
09/207910 |
|
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
07/619825 |
Nov 1990 |
US |
Child |
07/944705 |
|
US |
Parent |
07/456790 |
Dec 1989 |
US |
Child |
07/619825 |
|
US |
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
08/144265 |
Oct 1993 |
US |
Child |
08/329000 |
|
US |
Parent |
07/969383 |
Oct 1992 |
US |
Child |
08/144265 |
|
US |
Parent |
07/788269 |
Nov 1991 |
US |
Child |
07/969383 |
|
US |
Parent |
07/944705 |
Sep 1991 |
US |
Child |
07/788269 |
|
US |
Parent |
07/354411 |
May 1989 |
US |
Child |
07/456790 |
|
US |
Reissues (1)
|
Number |
Date |
Country |
Parent |
08/466895 |
Jun 1995 |
US |
Child |
09/207910 |
|
US |